{
    "clinical_study": {
        "@rank": "68735", 
        "acronym": "DCE-MRI", 
        "arm_group": {
            "arm_group_label": "Meglumine Gadoterate", 
            "arm_group_type": "Experimental", 
            "description": "there is one single arm of patients (no comparative arm)"
        }, 
        "brief_summary": {
            "textblock": "Primary objective :\n\n      The main objective is to evaluate the value of DCE-MRI in prediction of response of patients\n      with HCC to treatment with Sorafenib assessed by mRECIST."
        }, 
        "brief_title": "DCE-MRI Using Dotarem\u00ae in Evaluation of Therapeutic Response to Sorafenib in Patients With Advanced Stage HCC", 
        "completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Hepatocellular Carcinoma", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Carcinoma, Hepatocellular"
            ]
        }, 
        "detailed_description": {
            "textblock": "Secondary objectives :\n\n        1. To evaluate the value of percent change of DCE-MRI/AFP/DWI from baseline to follow up\n           at 1 or 2 weeks in prediction of overall survival, progression-free survival, and time\n           to progression\n\n        2. To evaluate the value of baseline DCE-MRI/AFP/DWI in prediction of overall survival,\n           progression-free survival, and time to progression."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Age \u2265 20 years old\n\n          2. Subject diagnosed for Unresectable HCC (Child Pugh class A and major vascular\n             invasion, extrahapatic metastasis, or progression after TACE more than 2 times).\n\n          3. Presence of mRECIST target lesion (Lesion which can be classified as a RECIST\n             measurable lesion(can be measured \u2265 1 cm in at least one dimension), Lesion suitable\n             for repeat measure, Lesion showing intraluminal arterial enhancement on\n             contrast-enhanced CT or MRI) within liver\n\n          4. Patient planned to be treated with sorafenib\n\n          5. Patient with liver CT performed or planned to be performed within 4 weeks before\n             initiation of Sorafenib treatment\n\n          6. Patient with a life expectancy of 12 weeks or more\n\n          7. No previous treatment with Sorafenib\n\n          8. Subjects able to understand and having provided written informed consent to\n             participate in the trial.\n\n          9. Female subjects who are surgically sterilized, or post-menopausal (minimum 12 months\n             of amenorrhea) or who have a documented negative urine hCG test at screening\n\n        Exclusion Criteria:\n\n          1. Contraindication to MRI (e.g. : severe claustrophobia, pacemaker, metalic joint\n             replacement or any other according to the imaging center's standard practice)\n\n          2. Subjects presenting with known severe renal failure (estimated creatinine clearance <\n             30 ml/min calculated by the Cockcroft-Gault formula or estimated GFR <\n             30ml/min/1.73m\u00b2 by MDRD)\n\n          3. History of hypersensitivity reaction to a gadolinium contrast media\n\n          4. Female with child bearing potential without contraception using at least 2 different\n             methods\n\n          5. Breast feeding or pregnant female\n\n          6. Any condition which, based on the investigator's clinical judgment, would prevent the\n             patient from completing all trial assessments and visits (for example: mental or\n             physical incapacity, language comprehension, geographical localisation, etc\u2026)\n\n          7. Previous other therapy to a target lesion within 30 days\n\n          8. Previous radiation therapy to a target lesion\n\n          9. Subjects having participated in any investigational drug study within 30 days prior\n             the study inclusion or currently participating in another clinical trial involving an\n             Investigational Medicinal Product (IMP)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "65", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 6, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01806740", 
            "org_study_id": "DGD-44-057"
        }, 
        "intervention": {
            "arm_group_label": "Meglumine Gadoterate", 
            "description": "DCE-MRI is a method to measure the evaluated response", 
            "intervention_name": "Meglumine Gadoterate", 
            "intervention_type": "Drug", 
            "other_name": "Dotarem"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Gadolinium 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetate", 
                "Sorafenib"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "DCE-MRI", 
            "Sorafenib response"
        ], 
        "lastchanged_date": "November 6, 2013", 
        "location": {
            "contact": {
                "email": "jong-mi.lee@guerbet-group.com", 
                "last_name": "Jong Mi Lee, Master", 
                "phone": "+82-2-3453-1212"
            }, 
            "facility": {
                "address": {
                    "city": "Gangnam gu", 
                    "country": "Korea, Republic of", 
                    "state": "Seoul", 
                    "zip": "135-920"
                }, 
                "name": "Guerbet Korea"
            }, 
            "investigator": [
                {
                    "last_name": "Jeong Min Lee, Ph.D", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Chang Hee Lee, Ph.D", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Jin Young Choi, Ph.D", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Young Jun Lee, Ph.D", 
                    "role": "Principal Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase IV Study of DCE-MRI Using Dotarem\u00ae in Evaluation of Therapeutic Response to Sorafenib in Patients With Advanced Stage HCC", 
        "other_outcome": {
            "description": "Check NSsaFe occurrence at the termination.", 
            "measure": "NSsaFe occurrence", 
            "safety_issue": "Yes", 
            "time_frame": "1 year"
        }, 
        "overall_contact": {
            "email": "jong-mi.lee@geurbet-group.com", 
            "last_name": "Jong Mi Lee, Master", 
            "phone": "+82-2-3453-1212"
        }, 
        "overall_official": {
            "affiliation": "Seoul National University Hospital", 
            "last_name": "Jeong Min Lee, Ph.D", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To evaluate the correlation between % change of DCE-MRI perfusion parameters (Ktrans, AUC, kep, ve,Etc.) from baseline to follow up image at 1 & 2 weeks and the response to Sorafenib assessed by mRECIST at 2 months after initiation of treatment", 
            "measure": "correlation between % change of DCE-MRI perfusion parameters", 
            "safety_issue": "No", 
            "time_frame": "3 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01806740"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "To evaluate the correlation between % change of DCE-MRI perfusion parameters (Ktrans, AUC, kep, ve, Etc.)/AFP/DWI from baseline to follow up at 1 & 2weeks and OS/PFS/TTP", 
                "measure": "correlation between DCE-MRI perfusion parameters and other data", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "description": "To evaluate the correlation between DCE-MRI perfusion parameters/AFP/DWI at baseline and OS/PFS/TTP", 
                "measure": "correlation between DCE-MRI perfusion parameters and other data", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }
        ], 
        "source": "Guerbet", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Guerbet", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}